MRSA carriership - Methicillin resistant Staphylococcus aureus carriership
Conditions
Interventions
Group A: doxycycline 200 mg q.d. - rifampicin 600mg b.i.d. versus Group B:
trimethoprim 200mg b.i.d. - rifampicin 600mg b.i.d. All orally, total duration
7 days.
Sponsors
Leids Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: complicated MRSA carriership Adult
Exclusion criteria
Exclusion criteria: - catheters/drains in situ - Failure of previous decolonization attempt of complicated MRSA carriage - Allergy or other contra-indication to either doxycycline, rifampicin or trimethoprim (these patients will participate in the observational arm) - Previous participation in this study - Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study endpoint is the success rate of MRSA decolonization. Successful decolonization is defined as 3 consecutive negative cultures after treatment, with a minimum interval of 7 days. | — |
Secondary
| Measure | Time frame |
|---|---|
| - The long-term success rate of decolonization treatment of doxycycline-rifampicin compared to trimethoprim-rifampicin, defined as an additional set of negative MRSA swabs taken 2 months and 1 year after decolonization treatment. - To determine whether there is an association between virulence factors and success rate of decolonization. | — |
Countries
Netherlands
Outcome results
None listed